Physician profile
Gary Gerald Singer
NPI 1366439283
$169,900.87
in general payments reported to CMS, 2019-2025
38 companies · $8,807 in 2025
The $8,807 reported for 2025 was more than what 95% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32K · 2020: $12K · 2021: $34K · 2022: $40K · 2023: $21K · 2024: $22K · 2025: $8,807.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Consulting Fee: $14K · Grant: $5,000 · Food and Beverage: $4,715 · Honoraria: $3,000 · Travel and Lodging: $1,068 · Entertainment: $199 · Education: $97.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23,927.50 |
| Consulting Fee | $14,220.00 |
| Grant | $5,000.00 |
| Food and Beverage | $4,714.55 |
| Honoraria | $3,000.00 |
| Travel and Lodging | $1,067.82 |
| Entertainment | $199.10 |
| Education | $97.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $73,246.66 | 2019-2024 | Veltassa, Korsuva |
| Astrazeneca Pharmaceuticals LP | $70,929.95 | 2019-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $16,393.29 | 2021-2025 | |
| Fresenius USA Marketing, INC. | $3,422.12 | 2019-2025 | Korsuva, Nxstage System One, Liberty Select Cycler |
| Quanta Dialysis Technologies INC | $2,199.10 | 2023 | Sc+ Hemodialysis Machine |
| Amgen INC. | $445.64 | 2019-2025 | Krystexxa, Tavneos, Aranesp |
| Janssen Pharmaceuticals, INC | $390.05 | 2019-2020 | |
| Travere Therapeutics, INC. | $371.59 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $293.29 | 2023-2025 | |
| Akebia Therapeutics INC | $286.60 | 2019-2025 | Vafseo, Auryxia |
| Nxstage Medical, INC. | $265.24 | 2019-2024 | |
| Novo Nordisk INC | $152.10 | 2024-2025 | Ozempic |
| Apellis Pharmaceuticals, INC. | $138.62 | 2025 | |
| Medtronic, INC. | $133.70 | 2025 | Symplicity G3 |
| Astrazeneca Uk Limited | $129.89 | 2025 | Lokelma |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $125.00 | 2023 | Injectafer |
| Vantive US Healthcare LLC | $117.17 | 2025 | Renal - Pd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.57 | 2023-2025 | Jardiance |
| Genentech USA, INC. | $90.52 | 2025 | Gazyva |
| Otsuka America Pharmaceutical, INC. | $84.49 | 2019-2024 | Jynarque |
| Calliditas Therapeutics US INC. | $66.38 | 2024-2025 | Tarpeyo |
| Glaxosmithkline, LLC. | $62.53 | 2024-2025 | Benlysta |
| Covidien LP | $57.96 | 2019 | |
| Horizon Therapeutics Plc | $51.44 | 2019-2023 | Krystexxa |
| Shire North American Group INC | $47.00 | 2019 | |
| Ardelyx, INC. | $43.81 | 2024 | Ibsrela |
| Mallinckrodt Enterprises LLC | $41.13 | 2019 | |
| Cormedix INC. | $28.76 | 2024 | Defencath |
| Opko Pharmaceuticals, LLC | $24.81 | 2019 | |
| Alnylam Pharmaceuticals INC. | $23.04 | 2025 | Givlaari |
| Mallinckrodt Hospital Products INC. | $22.62 | 2020 | |
| Scpharmaceuticals INC. | $21.34 | 2025 | |
| Baxter Healthcare | $20.41 | 2019 | |
| Aurinia Pharma U.S., INC. | $17.96 | 2025 | Lupkynis |
| Bard Peripheral Vascular, INC. | $17.00 | 2020 | |
| Pfizer INC. | $14.88 | 2024 | |
| Ultragenyx Pharmaceutical INC. | $14.21 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Singer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.